CAS 2800223-30-5 | TYRA-300

Product introduction:

 

Appearance: Off-white to white crystalline powder

Nature: Orally bioavailable, reversible, highly selective FGFR3 kinase inhibitor

 

Application:

1 Clinical Oncology 

Metastatic Urothelial Cancer (mUC):

First-line / second-line therapy for patients with FGFR3 mutations/fusions

Phase II SURF301 trial (ongoing)

Non-Muscle Invasive Bladder Cancer (NMIBC):

For recurrent/refractory, low-grade, FGFR3-altered disease

Phase II SURF302 study (primary endpoint: 3-month CR rate)

Other Solid Tumors:

Evaluated in FGFR3-aberrant upper tract urothelial carcinoma (UTUC)

2 Genetic Skeletal Disorders

Achondroplasia (ACH, most common dwarfism):

Targets FGFR3 G380R activating mutation

Promotes chondrocyte proliferation/growth plate maturation

Phase II BEACH301 pediatric trial

 

Synonyms:

C25H24Cl2N6O3S

TYRA-300

2800223-30-5

(R) 5- (1- (3,5-dichloropyridin-4-yl) ethoxy) -3- (6- (6- (methylsulfonyl) -2,6-diazaspiro [3.3] heptan-2-yl) pyridin-3-yl) -1H-indazole

 

 

Hot Tags: cas 2800223-30-5 | tyra-300, China cas 2800223-30-5 | tyra-300 manufacturers, suppliers, api availability, api content filtering for api, api marketing automation api integration, api reliability, api synchronous calls, Cefprozil hydrate